CalciMedica, Inc.
CALCNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$23.1M | −$24.2M | −$38.1M | −$14.2M | −$35.9M | −$29.8M |
| Net income | −$29.6M | −$13.7M | −$34.4M | −$7.8M | −$35.8M | −$27.5M |
| Total assets | $13.6M | $19.8M | $12.2M | $3.3M | $69.1M | $101.8M |
| Total liabilities | $20.2M | $5.4M | $4.0M | $12.6M | $4.1M | $7.0M |
| Equity | −$6.6M | $14.4M | $8.2M | −$71.3M | $65.0M | $94.8M |
| EPS (diluted) | $-1.97 | $-1.22 | $-7.66 | $-111.16 | $-1.69 | — |
| Shares out. | 13.5M | 10.7M | 22.0M | 21.4M | 21.0M | 21.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 445.1%
- Return on assets
- −217.5%
- Return on capital (ROCE)
- −235.7%
- Liabilities / assets
- 148.9%
- Debt / equity
- —
- Book value / share
- $-0.49
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -52.48distress
- Accruals / assets
- −61.7%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 2 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Chernett JoreyPassive (13G)May 20, 2026
- Soleus Private Equity Fund Iii, L.P.Passive (13G)May 8, 2026
- Flynn James EPassive (13G)Feb 6, 2026
- Bering Partners Ii Gp, L.L.C.Passive (13G)Oct 29, 2025
- Avenue Venture Opportunities Fund Ii, L.P.Passive (13G)Sep 9, 2025
- Alafi Capital Co LlcPassive (13G)Aug 5, 2025
- Stonepine Capital Management, LlcPassive (13G)May 14, 2025
- Aisling Capital V, LpPassive (13G)Mar 3, 2025
- Revelation Healthcare Fund I, L.P.Passive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 136,411 | 1.0 | -18.8% |
| Apr 30, 2026 | 167,953 | 1.1 | -54.9% |
| Apr 15, 2026 | 372,157 | 1.5 | +10.1% |
| Mar 31, 2026 | 337,917 | 1.4 | -26.4% |
| Mar 13, 2026 | 459,110 | 1.0 | +17.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 12, 2026
- Delisting / listing-standard noticeMar 18, 2026
- Results of operationsMar 3, 2026
- Other material eventJan 28, 2026
- Regulation FD disclosure · Other material eventJan 28, 2026
- Results of operationsNov 12, 2025
- Other material eventNov 6, 2025
- Results of operationsAug 12, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.